Department of Medicine, University of Alberta Hospital, Edmonton, Canada.
Paediatric Hepatology & Paediatric Liver Transplant Department, Reference Center for Rare Paediatric Liver Diseases, FILFOIE, ERN RARE LIVER, Assistance Publique-Hôpitaux de Paris, Faculty of Medicine and University Paris-Saclay, CHU Bicêtre, Le Kremlin-Bicêtre, France.
BMC Med Genet. 2020 Nov 30;21(1):238. doi: 10.1186/s12881-020-01173-0.
Progressive familial intrahepatic cholestasis (PFIC) type 3 is an autosomal recessive disorder arising from mutations in the ATP-binding cassette subfamily B member 4 (ABCB4) gene. This gene encodes multidrug resistance protein-3 (MDR3) that acts as a hepatocanalicular floppase that transports phosphatidylcholine from the inner to the outer canalicular membrane. In the absence of phosphatidylcholine, the detergent activity of bile salts is amplified and this leads to cholangiopathy, bile duct loss and biliary cirrhosis. Patients usually present in infancy or childhood and often progress to end-stage liver disease before adulthood.
We report a 32-year-old female who required cadaveric liver transplantation at the age of 17 for cryptogenic cirrhosis. When the patient developed chronic ductopenia in the allograft 15 years later, we hypothesized that the patient's original disease was due to a deficiency of a biliary transport protein and the ductopenia could be explained by an autoimmune response to neoantigen that was not previously encountered by the immune system. We therefore performed genetic analyses and immunohistochemistry of the native liver, which led to a diagnosis of PFIC3. However, there was no evidence of humoral immune response to the MDR3 and therefore, we assumed that the ductopenia observed in the allograft was likely due to chronic rejection rather than autoimmune disease in the allograft.
Teenage patients referred for liver transplantation with cryptogenic liver disease should undergo work up for PFIC3. An accurate diagnosis of PFIC 3 is key for optimal management, therapeutic intervention, and avoidance of complications before the onset of end-stage liver disease.
进行性家族性肝内胆汁淤积症 3 型(PFIC3)是一种常染色体隐性遗传病,由 ATP 结合盒亚家族 B 成员 4(ABCB4)基因突变引起。该基因编码多药耐药蛋白 3(MDR3),作为胆盐从内向胆小管膜转运的磷脂酰胆碱的翻转酶。在没有磷脂酰胆碱的情况下,胆盐的去污剂活性被放大,导致胆管病、胆管丢失和胆汁性肝硬化。患者通常在婴儿期或儿童期发病,常在成年前进展为终末期肝病。
我们报告了一名 32 岁女性,17 岁时因隐源性肝硬化接受了尸体肝移植。15 年后,当患者在移植物中出现慢性胆管减少时,我们假设患者的原有疾病是由于胆汁转运蛋白缺乏引起的,而胆管减少可能是由于免疫系统以前未遇到的新抗原的自身免疫反应引起的。因此,我们进行了遗传分析和对供肝的免疫组化染色,最终诊断为 PFIC3。然而,没有证据表明对 MDR3 存在体液免疫反应,因此,我们假设在移植物中观察到的胆管减少可能是由于慢性排斥反应,而不是移植物中的自身免疫疾病。
因隐源性肝病而被转诊进行肝移植的青少年患者应进行 PFIC3 的检查。PFIC3 的准确诊断是优化管理、治疗干预和避免终末期肝病发生前并发症的关键。